Pyrrolidin-2-one derivatives may reduce body weight in rats with diet-induced obesity.

No abstract is available for this paper.

• Publication year

  2016

• Venue

  European Journal of Pharmacology

• Publication date

  2016-04-05

• Fields of study

  Medicine, Chemistry

• Identifiers
  DOI 10.1016/j.ejphar.2016.02.047PMID 26896778
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• A Comparison of the Anorectic Effect and Safety of the Alpha2-Adrenoceptor Ligands Guanfacine and Yohimbine in Rats with Diet-Induced Obesity

  2015cited by this paper
• Critical roles of nardilysin in the maintenance of body temperature homoeostasis

  2014cited by this paper
• Synthesis and biological evaluation of 3-methyl-5-phenylthieno[2,3-d]pyrimidine-2,4(1H,3H)-dione derivatives for the treatment of diet-induced obesity.

  2014cited by this paper
• Modulation of adipose tissue thermogenesis as a method for increasing energy expenditure.

  2014cited by this paper
• Changes in body weight and blood pressure: paradoxical outcome events in overweight and obese subjects with cardiovascular disease

  2014cited by this paper
• Validation of an enzyme-linked immunosorbent assay developed for measuring cortisol concentration in human saliva and serum for its applicability to analyze cortisol in pig saliva

  2014cited by this paper
• Fat cells directly sense temperature to activate thermogenesis

  2013cited by this paper
• Characterization of the hypothermic effects of imidazoline I2 receptor agonists in rats

  2012cited by this paper
• The utility of animal models to evaluate novel anti‐obesity agents

  2011cited by this paper
• Antidepressant-like activity of thephenylpiperazinepyrrolidin-2-one derivatives in mice

  2011cited by this paper
• Synthesis and pharmacological evaluation of pyrrolidin-2-one derivatives as antiarrhythmic, antihypertensive and alpha-adrenolytic agents.

  2010cited by this paper
• Synthesis and pharmacological evaluation of pyrrolidin-2-one derivatives as antiarrhythmic, antihypertensive and α-adrenolytic agents

  2010cited by this paper
• Catecholamine-induced lipolysis in adipose tissue and skeletal muscle in obesity.

  2008cited by this paper
• Yohimbine Attenuates Baroreflex-Mediated Bradycardia in Humans

  2007cited by this paper
• Yohimbine in the treatment of orgasmic dysfunction.

  2007cited by this paper
• Adipose tissue lipolysis as a metabolic pathway to define pharmacological strategies against obesity and the metabolic syndrome.

  2006cited by this paper
• Clinical efficacy and tolerability of alpha-blocker doxazosin as add-on therapy in patients with hypertension and impaired glucose metabolism.

  2006cited by this paper
• Alpha(2)-adrenergic receptor signalling in hypertension.

  2005cited by this paper
• α2-Adrenergic receptor signalling in hypertension

  2005cited by this paper
• Human fat cell lipolysis: biochemistry, regulation and clinical role.

  2005cited by this paper
• Gender- and site-related effects on lipolytic capacity of rat white adipose tissue

  2003cited by this paper
• High-fat diet-induced hyperglycemia and obesity in mice: differential effects of dietary oils.

  1996cited by this paper
• High fat diet-induced hyperglycemia: prevention by low level expression of a glucose transporter (GLUT4) minigene in transgenic mice.

  1995cited by this paper
• Techniques for the measurement of white adipose tissue metabolism: a practical guide.

  1995cited by this paper
• Determination of "free" glycerol in human serum reference materials by isotope-dilution gas chromatography-mass spectrometry.

  1992cited by this paper
• Alpha-2 adrenoceptors in lipolysis: alpha 2 antagonists and lipid-mobilizing strategies.

  1992cited by this paper
• Thermogenic and lipolytic effect of yohimbine in the dog

  1991cited by this paper
• Regional variation in adipose tissue lipolysis in lean and obese men.

  1991cited by this paper
• Lipomobilizing effects of procaterol and yohimbine in the conscious dog: comparison of endocrinological, metabolic and cardiovascular effects

  1989cited by this paper

• Metabolic and cardiovascular benefits and risks of 4-hydroxy guanabenz hydrochloride: α2-adrenoceptor and trace amine-associated receptor 1 ligand

  2023cites this paper
• Histamine H3 Receptor Ligands—KSK-59 and KSK-73—Reduce Body Weight Gain in a Rat Model of Excessive Eating

  2021cites this paper
• Influence of betahistine repeated administration on a weight gain and selected metabolic parameters in the model of excessive eating in rats.

  2021cites this paper
• Multifunctional Arylsulfone and Arylsulfonamide-Based Ligands with Prominent Mood-Modulating Activity and Benign Safety Profile, Targeting Neuropsychiatric Symptoms of Dementia

  2021cites this paper
• A Metabolomic Analysis of the Sex-Dependent Hispanic Paradox

  2021cites this paper
• Antidepressant-like activity and safety profile evaluation of 1H-imidazo[2,1-f]purine-2,4(3H,8H)-dione derivatives as 5-HT1A receptor partial agonists

  2020cites this paper
• Structural modifications in the distal, regulatory region of histamine H3 receptor antagonists leading to the identification of a potent anti-obesity agent.

  2020cites this paper
• Are the Hydantoin-1,3,5-triazine 5-HT6R Ligands a Hope to a Find New Procognitive and Anti-Obesity Drug? Considerations Based on Primary In Vivo Assays and ADME-Tox Profile In Vitro

  2019cites this paper
• KSK19 - novel histamine H3 receptor ligand reduces body weight in diet induced obese mice.

  2019cites this paper
• A Simple and Facile Synthesis of 4‐Phenylquinoline‐fused Pyrrolidin‐2‐ones

  2018cites this paper
• Metabolic and Cardiovascular Benefits and Risks of EMD386088—A 5-HT6 Receptor Partial Agonist and Dopamine Transporter Inhibitor

  2017influential citation
• Diastereoselective Synthesis of Rauhut-Currier-Type Adducts via an Unexpected α-Addition of α,β-Unsaturated γ-Butyrolactams to Coumarin Derivatives.

  2017cites this paper
• Metabolic benefits of 1-(3-(4-(o-tolyl)piperazin-1-yl)propyl)pyrrolidin-2-one: a non-selective α-adrenoceptor antagonist

  2017cites this paper
• H3 histamine receptor antagonist pitolisant reverses some subchronic disturbances induced by olanzapine in mice

  2016cites this paper
• HBK-14 and HBK-15 Do Not Influence Blood Pressure, Lipid Profile, Glucose Level, or Liver Enzymes Activity after Chronic Treatment in Rats

  2016cites this paper